Providing market research reports, industry analysis, company profiles and country reports for strategic planning, competitive intelligence, marketing and business research.
Search for Market Research Reports:    

Market Dynamics: Antipsychotics - A Market Driven by Reformulation

Published by: Datamonitor

Published: Oct. 21, 2002 - 160 Pages


Table of Contents


Overview

Introduction

The report will discuss the key issues impacting the global antipsychotic market. This includes the movement of atypical neuroleptics into new markets such as mania, the likely impact of new drugs such as Abilitat and Zomaril on
current products, the growth of novel formulations for key drugs, the impact of the NICE decision in the UK and the refusal by the FDA to approve Risperdal Consta




DRIVERS AND TRENDS

The antipsychotic market is entering the lifecycle stage of reformulations, and these will have a large impact on the market because drugs in the late stage pipeline not clinically differentiate from currently marketed drugs due to use of the same principal receptors. A common trend is to reformulate into short term and long-term intramuscular (IM) depots. The short-term depots target agitated acute psychosis patients, where the drug delivery is critical in order to administer medication. The formulation has the excellent commercial benefit of offering a switch to the oral formulation once stabilized, reducing the risk of relapse. Long-term IM depots target maintenance therapy and specifically patients who have compliance issues, and the formulation offers an incentive to the physician to use the oral formulation previously in order to latter switch to the reformulation.




ANTIPSYCHOTIC MARKET DEFINITION

Description of the principal indications that antipsychotic manufactures target—schizophrenia and bipolar disorder (BD)—and their prevalence by geographical region. In addition, other psychosis disorders that can be targeted off-label are described in order to provide an understanding of the psychosis spectrum.



MIXED NEUROTRANSMITTER RECEPTOR ANTAGONISTS

Analysis of clinical data and market positioning of the key mixed neurotransmitter receptor antagonists (MNRAs). Each drug is subjected to a SWOT analysis, including marketing strength, clinical trials for new indications, threats of new launches and reformulations and much more.



DOPAMINE ANTAGONISTS

SWOT Analyses of key dopamine antagonists.



COMPARISON OF KEY BRANDS

Comparison of key atypical brands from all classes is provided.



MARKET INSIGHT AND LIFECYCLE MANAGEMENT

In-depth analysis of the clinical and market positioning of reformulations on the market and late-stage development. In addition, a strategic analysis of Seroquel and Geodon id provided.




COUNTRY ANALYSIS

Country specific analysis of the antipsychotic market. Each regional section identifies key drivers in the market and analyses how they will affect the market. Drivers include atypical antipsychotic launches, government initiatives and reimbursement issues.




DATASETS

Table 1: Key antipsychotic market parameters, 2002-10

Table 2: Top five antipsychotics in 2010 and respective growths

Table 3: Gold standard comparison by indication and class, 2002

Table 4: MNRA key facts, 2002

Table 5: Zyprexa: key facts

Table 6: Examples of off-label olanzapine use in recent clinical trials

Table 7: Forecast revenues for Zyprexa, 2002-10

Table 8: Factors impacting Zyprexa’s revenue stream, 2002-10.

Table 9: Risperdal: key facts

Table 10: Examples of off-label risperidone use in recent clinical trials

Table 11: Risperdal forecast revenues, 2002-10

Table 12: Factors impacting Risperdal’s revenue stream, 2002-10

Table 13: Seroquel: key facts

Table 14: Examples of off-label risperidone use in recent clinical trials

Table 15: Forecast revenues for Seroquel, 2002-10

Table 16: Factors impacting Seroquel’s revenue stream, 2002-10

Table 17: Geodon: key facts

Table 18: Examples of off-label ziprasidone’s use in recent clinical trials

Table 19: Forecast revenues for Geodon, 2002-10

Table 20: Factors impacting Geodon’s revenue stream, 2002-10

Table 21: Clozaril: key facts

Table 22: Forecast revenues for Clozaril, 2002-10

Table 23: Factors impacting Clozaril’s revenue stream, 2002-10

Table 24: Dopamine antagonist brands details, 2002

Table 25: Solian: key facts

Table 26: Examples of off-label amisulpride use in recent clinical trials

Table 27: Forecast revenues for Solian, 2002-10

Table 28: Factors impacting Solian’s revenue stream, 2002-10.

Table 29: R&D products included in antipsychotic global forecast, 2002- 2010

Table 30: Forecast atypical antipsychotic sales, 2002-10

Table 31: Reformulations of antipsychotic brands, 2002

Table 32: PANSS-EC efficacy ratings for IM depots in acute schizophrenia patients

Table 33: Global antipsychotic revenues and market share, 2000-2001

Table 34: Global revenues of key typical neuroleptics, 2000-2001

Table 35: Breakdown of the global antipsychotic market by country, 2000-2001

Table 36: Breakdown of antipsychotic market by class, 2001

Table 37: US sales and growth of key antipsychotics, 2000-2001

Table 38: Japanese antipsychotics market, 2000-01

Table 39: French antipsychotics market, 2000-01

Table 40: German antipsychotics market, 2000-01

Table 41: Italian antipsychotics market, 2000-01

Table 42: Spanish antipsychotic market, 2000-01

Table 43: US sales and growth of key antipsychotics, 2000-2001

Table 44: Antipsychotics market forecast, 2002—10

Table 45: Key market events and impact

Table 46: Forecast in the event of Zyprexa gaining an FDA contraindication for diabetes in mid-2003

Table 46: Confidence ratings for market sizes

Table 47: Confidence ratings for sales figures

Table 48: Confidence limits for global atypical sales

Table 49: Confidence limits for US market sales

Table 50: Confidence limits for Japanese market sales

Table 51: Confidence limits for French market sales

Table 52: Confidence limits for German markets sales

Table 53: Confidence limits from Spanish market

Table 54: Confidence limits for Spanish market sales

Table 55: Confidence limits for UK market sales

Table 56: Exchange rates used in this report, 2001

Abstract

Introduction: The antipsychotic market is moving into a new competitive environment with the forthcoming launches of new formulations. Short-term intramuscular (IM) depots of Pfizer's Geodon (ziprasidone) and Eli Lilly's Zyprexa (olanzapine) are to reach the market by 2003, targeting acute psychosis. How will the formulations ramp-up prescriptions of the respective oral formulations, and how much pressure will be placed on other antipsychotics to maintain their share of newly diagnosed patients? Scope: * Key data and market dynamics across the seven leading markets: the US, Japan, Germany, France, Italy, Spain, and the UK * Special focus on the mixed neurotransmitter receptor antagonists class and how the new formulations will alter the market dynamics * Detailed analysis of the Geodon and Seroquel growth strategies and how they are different from the market leaders * Focus on new formulations including a critique of clinical data and market positioning * Forecast revenues up to 2010 and analysis of impacting factors. Report Highlights: Eli Lilly's Zyprexa (olanzapine) has a wide range of products on the market and in development. This will lead to treatment flexibility, and attract physicians to prescribing the brand. Janssen's Risperdal Consta is highly anticipated by the industry and supported by good clinical trials. The formulation will be targeted towards maintenance therapy a will also ramp-up revenues of the oral formulation. Geodon's short term IM depot will receive a high uptake and be able to command a high price point. In addition, patients will be switched over to the oral formulation once stabilized. Reasons to Purchase: * Optimize your knowledge of company strategies in the antipsychotic market. * Enhance your sales forecasting ability and future product positioning through identification of market drivers. * Understand how reformulations for products already on the market can increase the rate of uptake for all products of the brand. * Review successful lifecycle management strategies through case studies of Geodon and Seroquel * Increase your competitive intelligence by accessing company profiles and assessments of product performance to 2010

Get Full Details About This Report >>
US: 800.298.5699
Int'l: +1.240.747.3093
Buy this Report
Price and Delivery Options
Search Inside Report


 

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 160,000 market research reports, company profiles and country profiles from over 600 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.

 

© MarketResearch.com 2008